Evidence map›Paper›PMID 33447638›Full record

ArticleOpen forum infectious diseases2021

Associations Between Tenofovir Diphosphate in Dried Blood Spots, Impaired Physical Function, and Fracture Risk.

Mona Abdo, Ryan P Coyle, Sharon M Seifert, Jose R Castillo-Mancilla, Catherine M Jankowski, Samantha Mawhinney, Peter L Anderson, Kristine M Erlandson

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mona AbdoDepartment of Epidemiology, Colorado School of Public Health, Aurora, Colorado, USA.
Ryan P CoyleDivision of Infectious Diseases, School of Medicine, University of Colorado-Anshutz Medical Campus, Aurora, Colorado, USA.
Sharon M SeifertSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado- Anshutz Medical Campus, Aurora, Colorado, USA.
Jose R Castillo-MancillaDivision of Infectious Diseases, School of Medicine, University of Colorado-Anshutz Medical Campus, Aurora, Colorado, USA.
Catherine M JankowskiCollege of Nursing, University of Colorado-Anshutz Medical Campus, Aurora, Colorado, USA.
Samantha MawhinneyDepartment of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado, USA.
Peter L AndersonSkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado- Anshutz Medical Campus, Aurora, Colorado, USA.
Kristine M ErlandsonDivision of Infectious Diseases, School of Medicine, University of Colorado-Anshutz Medical Campus, Aurora, Colorado, USA.
University of Colorado Anschutz Medical Campus · USColorado School of Public Health · US

Funding

NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI JANINE A HIGGINS · 1995 to 2026
$32.6M
University of Colorado Aging Training GrantT32AG000279 · NIA · UNIVERSITY OF COLORADO DENVER · PI Kerrie Moreau · 2001 to 2026
$10.1M
The High-Intensity Exercise to Attenuate Limitations and Train Habits (HEALTH) in Older Adults with HIVR01AG066562 · NIA · UNIVERSITY OF COLORADO DENVER · PI ERLANDSON, KRISTINE MACE, WEBEL, ALLISON R · 2020 to 2024
$4.3M
Predictors of Recovery and the App-Facilitated Tele-Rehabilitation (AFTER) Program for COVID SurvivorsR01AG054366 · NIA · UNIVERSITY OF COLORADO DENVER · PI ERLANDSON, KRISTINE MACE · 2016 to 2020
$3.4M
UNIVERSITY OF COLORADO HIV RESEARCH TRAINING PROGRAMT32AI007447 · NIAID · UNIVERSITY OF COLORADO DENVER · PI CAMPBELL, THOMAS B. · 1992 to 2016
$2.8M
NCATS NIH HHS UL1 TR002535NIAID NIH HHS T32 AI007447NIA NIH HHS R01 AG054366NIA NIH HHS R01 AG066562NIA NIH HHS T32 AG000279NIDDK NIH HHS P30 DK048520
6 · The paper itself

Abstract

backgroundIn this study, we evaluate associations between cumulative antiretroviral adherence/exposure, quantified using tenofovir diphosphate (TFV-DP) in dried blood spots (DBS), and human immunodeficiency virus (HIV)-related aging factors.

methodsThis is a cross-sectional analysis of younger (ages 18-35) and older (ages ≥60) persons with HIV (PWH) taking TFV disoproxil fumarate. Tenofovir diphosphate concentrations were quantified in DBS. Linear and logistic regression models were used to evaluate associations between TFV-DP and bone mineral density (BMD), physical function, frailty, and falls.

resultsForty-five PWH were enrolled (23 younger, 22 older). Every 500 fmol/punch (equivalent to an increase in ~2 doses/week) increase in TFV-DP was associated with decreased hip BMD (-0.021 g/cm

conclusionsHigher TFV-DP levels were associated with lower hip BMD, poorer physical function, and greater risk for falls, a concerning combination for increased fracture risk.

Indexed as

agingbone mineral densitydried blood spotsHIVtenofovir diphosphate

Identifiers

PMID33447638
PMCPMC7781095
OpenAlexW3108788935

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.